Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-01-27Clinical Trial Update: Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a conditioning regimen with Iodine-131 tositumomab plus etoposide and cyclophosphamide, followed by autolo…
-
CLINICAL_TRIALS trial_result · 2017-01-26Clinical Trial Update: Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
This ClinicalTrials.gov update reports on an observational study evaluating lenalidomide in patients with mantle cell lymphoma who failed ib…
-
CLINICAL_TRIALS trial_result · 2017-01-24Clinical Trial Update: Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
This update reports results from a phase 2 study of the BTK inhibitor ibrutinib in participants with relapsed or refractory mantle cell lymp…
-
CLINICAL_TRIALS trial_result · 2017-01-12Clinical Trial Update: Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma [Phase 2]
Phase 2 trial in Mantle Cell Lymphoma evaluating two Rituximab-based regimens (Rituximab/Bendamustine and Rituximab/Cytarabine); results wer…
-
CLINICAL_TRIALS trial_result · 2017-01-11Clinical Trial Update: The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of combining bortezomib with fludarabine and cytarabine in mantle cell lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-12-23Clinical Trial Update: Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 study evaluating a combination of bortezomib, rituximab, and yttrium-90 ibritumomab tiuxetan in relapsed or refractory low-grade, fo…
-
CLINICAL_TRIALS trial_result · 2016-12-22Clinical Trial Update: A Phase II Study of Doxycycline in Relapsed NHL [Phase 2]
Phase II trial of doxycycline in relapsed non-Hodgkin lymphoma was terminated and results were posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-12-07Clinical Trial Update: Cladribine in Patients With Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating cladribine in mantle cell lymphoma has completed. Sponsored by the Alliance for Clinical Trials in Oncology.
-
CLINICAL_TRIALS trial_result · 2016-12-06Clinical Trial Update: PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma [Phase 1, Phase 2]
Clinical trial update describing the evaluation of PCAR-119 Bridge Immunotherapy as a pre-transplant treatment for CD19-positive leukemias a…
-
CLINICAL_TRIALS withdrawal · 2016-11-07Clinical Trial Update: A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002) [Phase 2]
A Phase 2 trial of MK-4827 (niraparib) for mantle cell lymphoma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2016-11-03Clinical Trial Update: Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell [Phase 2]
Phase 2 trial evaluating a combination of gemcitabine, mitoxantrone (Novantrone), and rituximab for relapsed or refractory mantle cell lymph…
-
CLINICAL_TRIALS trial_result · 2016-10-25Clinical Trial Update: CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]
Clinical trial update on CD19-targeted CAR-T cell therapy being tested in relapsed/refractory leukemias and lymphomas (Phase 1 and Phase 2).
-
CLINICAL_TRIALS trial_result · 2016-10-05Clinical Trial Update: Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) [Phase 2]
This is a Phase 2 safety evaluation of combining ibritumomab tiuxetan (Zevalin) with a fludarabine-based reduced-intensity conditioning regi…
-
CLINICAL_TRIALS trial_result · 2016-08-29Clinical Trial Update: A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. [Phase 2]
Phase 2 trial evaluating Rituximab added to standard chemotherapy in untreated mantle cell lymphoma was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2016-08-17Clinical Trial Update: Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) [Phase 2]
A Phase 2 trial assessing salvage therapy with lenalidomide plus dexamethasone in patients with relapsed or refractory mantle cell lymphoma.
-
CLINICAL_TRIALS withdrawal · 2016-08-11Clinical Trial Update: Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 study of Rituximab, Romidepsin, and Lenalidomide for recurrent or refractory B-cell non-Hodgkin lymphoma has been withdraw…
-
CLINICAL_TRIALS trial_result · 2016-08-01Clinical Trial Update: Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]
Clinical trial update for PCAR-019 evaluating efficacy and safety in CD19-positive relapsed or refractory leukemia and lymphoma across Phase…
-
CLINICAL_TRIALS trial_result · 2016-07-21Clinical Trial Update: Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) [Phase 1, Phase 2]
Phase 1/2 trial assessing safety and initial efficacy of Obatoclax Mesylate in combination with Bortezomib for relapsed or refractory mantle…
-
CLINICAL_TRIALS trial_result · 2016-07-19Clinical Trial Update: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma [Phase 2]
A Phase 2 trial evaluated whether combination chemotherapy followed by peripheral stem cell transplantation is feasible for mantle cell lymp…
-
CLINICAL_TRIALS trial_result · 2016-07-19Clinical Trial Update: Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating chemotherapy and rituximab with peripheral stem cell transplantation for mantle cell lymphoma has comple…
-
FDA approval · 2016-06-23FDA Approved: BENDEKA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Bendeka (bendamustine hydrochloride) submitted by Teva Pharmaceuticals USA, Inc., indicating reg…
-
CLINICAL_TRIALS trial_result · 2016-06-01Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy [Phase 2]
This entry reports on a Phase 2 trial evaluating ibrutinib for mantle cell lymphoma in patients who progressed after bortezomib, with the st…
-
CLINICAL_TRIALS research · 2016-05-13Clinical Trial Update: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma [Phase 3]
Phase 3 trial update evaluating rituximab maintenance therapy for CD20-positive aggressive lymphoma and mantle cell lymphoma; no results are…
-
CLINICAL_TRIALS withdrawal · 2016-05-13Clinical Trial Update: A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma [Phase 3]
A Phase 3 trial evaluating acalabrutinib in combination with rituximab versus ibrutinib versus acalabrutinib in relapsed or refractory mantl…
-
CLINICAL_TRIALS trial_result · 2016-04-27Clinical Trial Update: Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating SyB L-0501 in combination with rituximab for untreated low-grade B-cell non-Hodgkin lymphoma and mantle cell lympho…